QuadMedicine KRX:464490KOSDAQ
쿼드메디슨 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, QuadMedicine reported an operating loss of ₩2.4bn. QuadMedicine (쿼드메디슨) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Clinical trial filing Swung to loss Screener
QuadMedicine quarterly results consolidated, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩2.4bn | −₩2.3bn |
| Q1 2026 | −₩4.4bn | −₩4.6bn |
| Q2 2025 | ₩34m | −₩370m |
| Q1 2025 | −₩3.4bn | −₩3.4bn |
| Q4 2024 derived | ₩971m | ₩942m |
| Q3 2024 | −₩895m | −₩1.3bn |
| Q2 2024 | −₩1.4bn | −₩1.4bn |
| Q1 2024 | −₩3.2bn | −₩3.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
QuadMedicine top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest QuadMedicine news Korean headlines
No articles yet.